Collaboration Announcement: Snowflake Inc. and SAP SE have partnered to integrate Snowflake's AI Data Cloud with SAP's Business Data Cloud, enhancing access to real-time data for AI applications and improving operational efficiency.
Integration Benefits: The collaboration allows for zero-copy data sharing, enabling businesses to analyze critical information without duplication, while also supporting large-scale analysis and maintaining governance.
Early Adoption: AstraZeneca is among the first to utilize this technology, leveraging it to accelerate medical research through real-time insights.
Future Developments: The SAP Snowflake integration is expected to be generally available in Q1 2026, with additional features and tools being introduced by both companies to enhance their AI capabilities.
Wall Street analysts forecast AZN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AZN is 102.75 USD with a low forecast of 95.00 USD and a high forecast of 108.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast AZN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AZN is 102.75 USD with a low forecast of 95.00 USD and a high forecast of 108.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 90.540
Low
95.00
Averages
102.75
High
108.00
Current: 90.540
Low
95.00
Averages
102.75
High
108.00
Deutsche Bank
Emmanuel Papadakis
Sell
maintain
2026-01-16
Reason
Deutsche Bank
Emmanuel Papadakis
Price Target
AI Analysis
2026-01-16
maintain
Sell
Reason
Deutsche Bank analyst Emmanuel Papadakis raised the firm's price target on AstraZeneca to 11,000 GBp from 10,500 GBp and keeps a Sell rating on the shares.
Barclays
James Gordon
NULL -> Overweight
upgrade
2026-01-06
Reason
Barclays
James Gordon
Price Target
2026-01-06
upgrade
NULL -> Overweight
Reason
Barclays analyst James Gordon raised the firm's price target on AstraZeneca to 16,500 GBp from 14,000 GBp and keeps an Overweight rating on the shares.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for AZN
Unlock Now
Goldman Sachs
downgrade
2026-01-05
Reason
Goldman Sachs
Price Target
2026-01-05
downgrade
Reason
Goldman Sachs analysts removed AstraZeneca from the firm's European Conviction List as part of its monthly update.
HSBC
Buy
upgrade
$95 -> $108
2025-12-10
Reason
HSBC
Price Target
$95 -> $108
2025-12-10
upgrade
Buy
Reason
HSBC raised the firm's price target on AstraZeneca to $108 from $95 and keeps a Buy rating on the shares as part of a 2026 outlook for the pharma group. The firm believes the sector is well positioned to outperform in 2026, "even more so if AI panic kicks in." HSBC's preferred stocks are "growth bucket ideas," but says "fallen angels and value could work as well."
About AZN
AstraZeneca PLC is a United Kingdom-based science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines. The Company operates across therapy areas, including Oncology; Cardiovascular, Renal and Metabolism (CVRM); Respiratory and Immunology (R&I); Vaccines and Immune Therapies (V&I), and Rare Disease. In the Oncology area, its key products include Tagrisso, Imfinzi, Calquence, Lynparza, and Enhertu. The key products of CVRM area include Farxiga/Forxiga, Brilinta/Brilique, Crestor, and Lokelma. In the R&I area, the key products are Symbicort, Fasenra, Breztri/Trixeo, and Tezspire. In the V&I Therapies area, the products are Beyfortus and FluMist. The products in the Rare Disease area are Ultomiris, Soliris, Strensiq, and Koselugo. It has about 191 projects in its development pipeline, including 19 new molecular entities (NMEs) in the late-stage pipeline. The Company distributes its products in over 125 countries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
